NFKB1 and myeloid leukemia: In agreement with our study, MG132 is known to block the degradation of the NF-κB inhibitor (I-κB) to inhibit the secretion of proinflammatory cytokines, resulting in the abolition of NF-kB activation in several cell types, including the human myeloid leukemia cell line U937 [29], dental pulp stem cells [30], mice gastrocnemius muscles [40], or the rat renal tubular epithelial cell line [41].